2021年生物制药行业报告（英）-56页_5mb

Biopharmaceutical Sector Update Summary

Core Content

This report provides an overview of the biopharmaceutical industry in 2020 and outlook for 2021, highlighting major developments, market trends, and key players. It emphasizes the impact of the global response to the COVID-19 pandemic, the evolution of biotech company formation, the role of capital markets, and recent advancements in cancer therapies and other therapeutic areas.

Main Points

2020: An Extraordinary Year

• COVID-19 Vaccines: Two vaccines were approved by the FDA in 2020, with high efficacy rates (e.g., Moderna's vaccine had 94.1% efficacy). Global coordination accelerated vaccine development, setting a new paradigm for future responses to emerging viruses.
• Market Performance: The biopharma market saw record fundraising, with $120.3 billion in equity raised in 2020, surpassing the previous high of $78.5 billion in 2018. This included $36.9 billion in venture capital, $63.6 billion in public follow-on equity, and $19.8 billion in IPOs.
• Balance Sheet Growth: The top 500 biotechs saw a significant increase in net cash, reaching $77 billion by Q3 2020, up from $48 billion the previous year. 214 companies had over $100 million in net cash, up from 151 in 2019.
• M&A Activity: AstraZeneca and Gilead were the largest users of M&A in 2020. Notable acquisitions include Roche acquiring Inflazome, J&J acquiring Bermekimab and Momenta, and AstraZeneca acquiring Alexion.
• Innovation in Therapeutics: There was a surge in innovation, particularly in areas like inflammasome and FcRn targets, with significant clinical progress reported for therapies targeting these pathways.

2021 Outlook

• Market Trends: The biotech market is expected to close 2021 higher than 2020, with a 73% statistical probability. The Nasdaq Biotech Index (NBI) was up 26% in 2020, indicating a positive trend.
• IPO and Equity Issuance: The IPO market is likely to remain strong in 2021, with a 50/50 chance of being up. Implied volatility (VIX) has started to normalize, historically associated with a stronger IPO market.
• Venture Capital: Venture capital fundraising reached an all-time high in 2020, with nearly $30 billion raised. This is expected to continue supporting biotech innovation and growth.

Key Implications

• Impact of the U.S. Election: The political situation in the U.S. is expected to influence the biopharma sector, particularly in terms of regulatory and policy changes.
• Global Market Shifts: The Chinese biopharma sector is growing rapidly and is now the second-largest by value, with Hengrui Medicine entering the global top 20.
• Pharma Market Changes: Viatris, formed by the merger of Pfizer's legacy business and Mylan, is positioned as a global leader in generic pharmaceuticals and is expected to have significant growth potential.

Important Cancer Advances

• Menin Inhibitors: Syndax and Kura are developing therapies targeting menin-MLL fusion proteins in AML, with promising Phase 1 results reported.
• Estrogen Receptor Knockout: Arvinas' PROTAC protein degrader, ARV-471, showed a 62% average ER knockout in Phase 1 trials for ER+ metastatic breast cancer.
• IL-15 Agonism: ImmunityBio's Anktiva® demonstrated significant efficacy in treating BCG-unresponsive NMIBC, with 72% complete response rate in Phase 2/3 trials.

Summary of Key Biotech Companies

• AbbVie: Successfully diversified its product base through major acquisitions, moving into the #3 position globally by value.
• Roche: Became the world's largest biopharma company by value, with a 43% increase in total value for the Chinese sector.
• Viatris: Launched in 2020 as a global leader in generics and off-patent brands, with a strong presence in multiple countries.

Future Monitoring Areas

• M&A Activity: Expected to continue with major players like J&J, Pfizer, and Roche likely to pursue significant deals.
• Biosimilars and Reimbursement: Changes in U.S. biosimilar usage rules and commercial uptake of digital therapeutics are key areas to watch.
• Biotech Innovation: Continued focus on precision medicine, adaptive trial designs, and other cutting-edge therapeutic approaches.

Conclusion

The biopharmaceutical sector experienced a transformative year in 2020, driven by rapid innovation, significant capital inflows, and the successful development of COVID-19 vaccines. These developments have set the stage for continued growth and advancement in 2021, with a focus on M&A, IPO activity, and emerging therapeutic areas. The sector is well-positioned for further success, supported by strong balance sheets, increased investment, and a shift towards more targeted and effective treatments.